drugset
drugset / Trial / NCT05317936

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

NCT05317936 ↗

Phase 1/2 Terminated 3 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To learn if the combination of LOXO-305 (pirtobrutinib) and venetoclax can help to control previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Timeline

Start
2022-11-16
Primary completion
2025-10-06
Completion
2025-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified — Oral
Subject Venetoclax Small molecule — Oral

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma